Date Title & Summary Additional Formats
December 21, 2021
Certara Announces FDA Renewal and Expansion of Certara’s Biosimulation Software for Reviewing Regulatory Submissions
FDA holds more than 400 Simcyp™ and Phoenix™ software licenses across 12 divisions and offices PRINCETON, N.J. , Dec. 21, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has renewed and
December 13, 2021
Certara Announces Release of Pinnacle 21 Enterprise Software
New metrics and analytics capabilities enable informed decision making for biopharmaceutical clients PRINCETON, N.J. , Dec. 13, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the feature release of Pinnacle 21 Enterprise 5.1.0, which updates
December 8, 2021
Certara to Host Investor Day on December 15, 2021
PRINCETON, N.J. , Dec. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, will host an Investor Day on Wednesday, December 15, 2021 from 3:00 PM to 6:00 PM ET in New York City . Certara’s management team will provide updates on the Company’s strategy,
December 2, 2021
Certara Announces Release of Simcyp™ Simulator Version 21, Expanding Capabilities to Align with Recent Regulatory Guidances
Simcyp Simulator has been used to inform more than 250 label claims for 85+ novel drugs PRINCETON, N.J. , Dec. 02, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Simulator Version 21, which updates the Company’s
November 29, 2021
Certara Announces Update of D360™ Scientific Informatics Software
New capabilities increase efficiency in analyzing and developing small molecules and biologic drugs PRINCETON, N.J. , Nov. 29, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of D360 version 21.5, an industry-leading scientific
November 22, 2021
Certara Announces Closing of Public Offering of Common Stock
PRINCETON, N.J. , Nov. 22, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the closing of its underwritten public offering of 10,000,000 shares of its common stock by certain existing stockholders at a public offering price of $31.00 per
November 17, 2021
Certara Announces Pricing of Public Offering of Common Stock
PRINCETON, N.J. , Nov. 17, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of 10 million shares of its common stock by certain existing stockholders (the “selling stockholders”) at a price to
November 15, 2021
Certara Announces Proposed Public Offering of Common Stock
PRINCETON, N.J. , Nov. 15, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a proposed underwritten public offering by certain selling stockholders of 10 million shares of its common stock pursuant to a registration statement filed with the
November 9, 2021
Certara Reports Third Quarter 2021 Financial Results
Raises full year 2021 guidance, reflecting strong revenue growth and the acquisition of Pinnacle 21 PRINCETON, N.J. , Nov. 09, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2021.
November 8, 2021
Certara Appoints James E. Cashman III as Chairman of Board of Directors
High-tech CEO with decades of experience supports continued innovation and growth PRINCETON, N.J. , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that James E. Cashman III, a current Board member, will be appointed Chairman of the
Displaying 1 - 10 of 49